Literature DB >> 33802466

HCV Core/NS3 Protein Immunization with "N-Terminal Heat Shock gp96 Protein (rNT (gp96))" Induced Strong and Sustained Th1-Type Cytokines in Immunized Mice.

Zamaneh Hajikhezri1, Farzin Roohvand2, Monireh Maleki3, Shohreh Shahmahmoodi1,4, Ali Akbar Amirzargar5,6, Abolfazl Keshavarz1, Negar Seyed7, Mohammad Farahmand1, Katayoun Samimi-Rad1.   

Abstract

Feeble cellular responses induced by T cell-based vaccines are a major challenge for the development of an effective vaccine against Hepatitis C virus (HCV) infection. To address this challenge, the potential of N-terminal fragment of gp96 heat shock protein (rNT (gp96) as an adjuvant was evaluated and compared to that of the CpG (as a recognized Th1-type adjuvant) in the formulation of HCV core/NS3 antigens in three immunization strategies of protein/protein, DNA/DNA, and DNA/protein. Immunized mice were evaluated for elicited immune responses in week 3 (W3) and 11 post-immunizations. Our results demonstrated that the protein (subunit) vaccine formulated with rNT (gp96) in protein/protein strategy (core/NS3 + gp96) was significantly more efficient than CpG oligodeoxynucleotides (CpG ODN) formulation and all other immunization strategies in the induction of Th1-type cytokines. This group of mice (core/NS3 + gp96) also elicited a high level of anti-Core-NS3 total immunoglobulin G (IgG) with dominant IgG2a isotype at W3. Thus, the co-administration of recombinant NT (gp96) protein with rHCV proteins might be a promising approach in the formulation of HCV subunit vaccine candidates for induction of high levels of Th1 cytokines and humoral responses.

Entities:  

Keywords:  Core-Ns3; Hepatitis C virus; prime-boost; rNT (gp96); vaccine

Year:  2021        PMID: 33802466      PMCID: PMC7999198          DOI: 10.3390/vaccines9030215

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  34 in total

Review 1.  Prime-boost strategies in DNA vaccines.

Authors:  C Jane Dale; Scott Thomson; Robert De Rose; Charani Ranasinghe; C Jill Medveczky; Joko Pamungkas; David B Boyle; Ian A Ramshaw; Stephen J Kent
Journal:  Methods Mol Med       Date:  2006

Review 2.  DNA Vaccines - A Modern Gimmick or a Boon to Vaccinology?

Authors:  Elanchezhiyan Manickan; Kevin L Karem; Barry T Rouse
Journal:  Crit Rev Immunol       Date:  2017       Impact factor: 2.214

3.  Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96.

Authors:  Leila Pishraft-Sabet; Anna D Kosinska; Sima Rafati; Azam Bolhassani; Tahereh Taheri; Arash Memarnejadian; Seyed-Moayed Alavian; Michael Roggendorf; Katayoun Samimi-Rad
Journal:  Arch Virol       Date:  2014-10-28       Impact factor: 2.574

Review 4.  Vaccine adjuvants: smart components to boost the immune system.

Authors:  Rakesh Bastola; Gyubin Noh; Taekwang Keum; Santosh Bashyal; Jo-Eun Seo; Jaewoong Choi; Yeonsu Oh; YoungSik Cho; Sangkil Lee
Journal:  Arch Pharm Res       Date:  2017-10-13       Impact factor: 4.946

5.  Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.

Authors:  G J Fernando; T J Stewart; R W Tindle; I H Frazer
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

6.  Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5.

Authors:  Yinling Lin; Taewoo Kwon; John Polo; Yi-Fei Zhu; Stephen Coates; Kevin Crawford; Christine Dong; Mark Wininger; John Hall; Mark Selby; Doris Coit; Angelica Medina-Selby; Colin McCoin; Philip Ng; Debbie Drane; David Chien; Jang Han; Michael Vajdy; Michael Houghton
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

7.  Heat shock protein gp96 adjuvant induces T cell responses and cross-protection to a split influenza vaccine.

Authors:  Ying Ju; Hongxia Fan; Jun Liu; Jun Hu; Xinghui Li; Changfei Li; Lizhao Chen; Qiang Gao; George F Gao; Songdong Meng
Journal:  Vaccine       Date:  2014-04-01       Impact factor: 3.641

8.  Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen.

Authors:  Ekaterina Alekseeva; Irina Sominskaya; Dace Skrastina; Irina Egorova; Elizaveta Starodubova; Eriks Kushners; Marija Mihailova; Natalia Petrakova; Ruta Bruvere; Tatyana Kozlovskaya; Maria Isaguliants; Paul Pumpens
Journal:  Genet Vaccines Ther       Date:  2009-06-08

9.  DNA vaccines: improving expression of antigens.

Authors:  Helen S Garmory; Katherine A Brown; Richard W Titball
Journal:  Genet Vaccines Ther       Date:  2003-09-16

10.  Safety Profile of a Multi-Antigenic DNA Vaccine Against Hepatitis C Virus.

Authors:  Jason Gummow; Makutiro G Masavuli; Zelalem A Mekonnen; Yanrui Li; Danushka K Wijesundara; Ashish C Shrestha; Ilia Voskoboinik; Eric J Gowans; Branka Grubor-Bauk
Journal:  Vaccines (Basel)       Date:  2020-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.